22
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2009
Study Completion Date
February 28, 2010
capecitabine
capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
topotecan
topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
lapatinib
lapatinib administered 1250mg once daily orally
GSK Investigational Site, Brussels
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Santiago de Compostela
GSK Investigational Site, Neo Faliro
GSK Investigational Site, Philadelphia
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Milan
GSK Investigational Site, Besançon
GSK Investigational Site, Cary
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Bremen
GSK Investigational Site, Spartanburg
GSK Investigational Site, Pamplona
GSK Investigational Site, Saint-Herblain
GSK Investigational Site, Valencia
GSK Investigational Site, Indianapolis
GSK Investigational Site, Petah Tikva
GSK Investigational Site, Ramat Gan
GSK Investigational Site, Troisdorf
GSK Investigational Site, Minneapolis
GSK Investigational Site, Rochester
GSK Investigational Site, Lille
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Zrifin
GSK Investigational Site, Heraklion, Crete
GSK Investigational Site, Paris
GSK Investigational Site, Dallas
GSK Investigational Site, Paris
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Portland
GSK Investigational Site, Sioux City
GSK Investigational Site, Boston
GSK Investigational Site, Albuquerque
GSK Investigational Site, Salzburg
GSK Investigational Site, Vienna
GSK Investigational Site, Edmonton
GSK Investigational Site, Vancouver
GSK Investigational Site, Québec
GSK Investigational Site, Perugia
GSK Investigational Site, Barcelona
GSK Investigational Site, Hospitalet de Llobregat, Barcelona
GSK Investigational Site, Uppsala
Lead Sponsor
GlaxoSmithKline
INDUSTRY